Target- |
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. |
First Approval Date23 Aug 2012 |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Higher diagnostic accuracy of 64Cu PET/CT compared to standard 18F-choline PET/CT in the detection rate of metastasis from prostate cancer.Phase III multicenter, sponsored, interventional open-label clinical study, with prospective enrollment. - 64CuCl2 PET/CT VS 18F-choline PET/CT in prostate cancer
Use of 64CuCl2 PET/CT Imaging in the selection of patients with prostate cancer in biochemical relapse after prostatectomy, to be successfully treated with salvage radiotherapy on the prostatic bed - 64CuCl2 PET/CT for cancer on the prostatic bed
100 Clinical Results associated with A.C.O.M. - Advanced Center Oncology Macerata - Srl
0 Patents (Medical) associated with A.C.O.M. - Advanced Center Oncology Macerata - Srl
100 Deals associated with A.C.O.M. - Advanced Center Oncology Macerata - Srl
100 Translational Medicine associated with A.C.O.M. - Advanced Center Oncology Macerata - Srl